Home>Topics>Companies>Amylin Pharmaceuticals

Amylin Pharmaceuticals

  1. All
  2. Commentary
  3. Headlines
  1. Human Genome and Glaxo Agree on $3.6 Billion Takeover Price Tag


    Mon, 16 Jul 2012

    and albiglutide, a once-weekly GLP-1 peptide that could be a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. The diabetes and cardiovascular markets are expansive, and darapladib and albiglutide could

  2. Bristol and Astra Announce Amylin Acquisition; Valuation Likely Unchanged for Big Pharma Firms


    Mon, 2 Jul 2012

    AstraZeneca AZN announced the acquisition of Amylin AMLN for $31 per share in an all-cash deal. Amylin 's board of directors unanimously recommended ..... tender their shares, so we plan to raise our Amylin fair value estimate to $31 as we don't

  3. Novo Sees Strong Growth in 1Q; Firm Preps for Likely Launch of New Insulins this Summer


    Fri, 27 Apr 2012

    first period since the drug's January 2010 launch with a sequential decline in revenue. First quarter saw the approval of Amylin 's AMLN rival GLP-1 drug Bydureon (which requires only once-weekly dosing compared with Victoza's once-daily requirement

  4. Bydureon's Launch Doesn't Offset Declining Byetta Sales for Amylin in the First Quarter


    Thu, 26 Apr 2012

    Amylin AMLN saw stagnant sales and its net loss widen during first quarter ..... keeping our fair value estimate in place, which reflects Amylin 's value on a stand-alone basis. Amylin reported net product sales of $150.6 million in first

  5. Human Genome's 1Q Overshadowed by Acquisition Speculation


    Wed, 25 Apr 2012

    albiglutide could also hit the market within the next few years as a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. Human Genome stands to receive royalties on worldwide sales of both products, should they become

  6. Amylin shares rise as it seeks buyers


    Mon, 23 Apr 2012

    (Reuters) - Shares of Amylin Pharmaceuticals Inc rose 12 percent in premarket trade following a Reuters report that the drug maker is seeking buyers after it spurned a $3.5 billion buyout offer from...

  7. Amylin Rejects $3.5 Billion Bid From Bristol; Offer Represents Premium to Firm's Stand-Alone Value


    Wed, 28 Mar 2012

    Shares of Amylin Pharmaceuticals AMLN skyrocketed Tuesday as it was revealed ..... our current fair value estimate for Amylin , which values the company on a stand ..... what we would expect a biotech of Amylin 's size and prospects to fetch

  8. Three Becomes Magic Number for Amylin ; Bydureon Finally Secures Approval in the U.S.


    Fri, 27 Jan 2012

    years in front of the Food and Drug Administration, Amylin AMLN and partner Alkermes finally succeeded in clinching approval ..... diabetes drug Bydureon, the once-weekly version of Amylin 's GLP-1 mimetic Byetta. We plan to raise our fair

  9. AMLN Under Review After Firm Calls It Quits With Longtime Partner Lilly


    Tue, 8 Nov 2011

    We are putting Amylin Pharmaceuticals AMLN under review following the company ..... exenatide franchise and the viability of Amylin itself has dramatically increased ..... projected modest contributions from Amylin -partnered products, and Lilly

  10. Amylin jumps on wider approval for diabetes drug


    Thu, 20 Oct 2011

    (Reuters) - Shares of Amylin Pharmaceuticals Inc climbed more than 15 percent in heavy trading on Thursday, a day after the U.S. health regulator approved wider use of its diabetes drug Byetta.

« Prev12345Next »
Content Partners